C12Y 208/02011
Galactosylceramide sulfotransferase
Official title: Galactosylceramide sulfotransferase (2.8.2.11)
C12Y208/02011 (Galactosylceramide sulfotransferase) appears on 10 US grants and 11 published applications in this corpus.
Search patents in C12Y- Granted patents
- 10
- Published applications
- 11
- Assignees
- 2
- Inventors
- 7
- Latest grant
- 21 May 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 1 | 0 |
| 2016 | 1 | 2 |
| 2017 | 0 | 0 |
| 2018 | 1 | 0 |
| 2019 | 2 | 3 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 1 | 1 |
| 2024 | 1 | 0 |
By publication year.
Recent patents
- Immunotherapy against neuronal and brain tumors21 May 2024US 11,986,497 B2Immatics Biotechnologies GmbH
- Immunotherapy against neuronal and brain tumors16 May 2023US 11,648,276 B2Immatics Biotechnologies GmbH
- Immunotherapy against neuronal and brain tumors14 Jul 2020US 10,709,735 B2Immatics Biotechnologies GmbH
- Immunotherapy against neuronal and brain tumors8 Oct 2019US 10,434,120 B2Immatics Biotechnologies GmbH
- Immunotherapy against neuronal and brain tumors24 Sep 2019US 10,420,800 B2Immatics Biotechnologies GmbH
- Novel immunotherapy against neuronal and brain tumors3 Aug 2023US 2023/0241111 A1Immatics Biotechnologies GmbH
- Novel immunotherapy against neuronal and brain tumors5 Nov 2020US 2020/0345777 A1Immatics Biotechnologies GmbH
- Novel immunotherapy against neuronal and brain tumors24 Oct 2019US 2019/0321405 A1Immatics Biotechnologies GmbH
- Novel immunotherapy against neuronal and brain tumors14 Mar 2019US 2019/0076476 A1Immatics Biotechnologies GmbH
- Novel immunotherapy against neuronal and brain tumors14 Mar 2019US 2019/0076477 A1Immatics Biotechnologies GmbH
Most cited
By later US patents
- Immunogenic epitope for immunotherapy117US 8,080,634 B2Immatics Biotechnologies GmbH · 2011
- Immunogenic epitopes for immunotherapy113US 9,511,128 B2Immatics Biotechnologies GmbH · 2016
- Immunogenic epitopes for immunotherapy106US 8,669,230 B2Immatics Biotechnologies GmbH · 2014
- Immunogenic epitopes for immunotherapy106US 9,950,048 B2Immatics Biotechnologies GmbH · 2018
- Immunotherapy against neuronal and brain tumors53US 10,420,800 B2Immatics Biotechnologies GmbH · 2019